Home > Insider Trading > Filing (0001062993-23-009310)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1695357	Provention Bio Inc.	PRVB	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1595849	Sessa Capital Im, L.p.	888 Seventh Avenue, 30Th Floor New York NY 10019	No	No	Yes	No
1618360	Sessa Capital (Master), L.p.	888 Seventh Avenue, 30Th Floor New York NY 10019	No	No	Yes	No
1618699	Sessa Capital Gp, Llc	888 Seventh Avenue, 30Th Floor New York NY 10019	No	No	Yes	No
1618700	Sessa Capital Im Gp, Llc	888 Seventh Avenue, 30Th Floor New York NY 10019	No	No	Yes	No
1618702	John Petry	888 Seventh Avenue, 30Th Floor New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-04-14	8,879,023	$6.00	17,758,046	No	4	X	Direct
Common Stock	Disposition	2023-04-14	2,190,549	$24.32	15,567,497	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Disposition	2023-04-14	8,879,023	$0.00	8,879,023	$6.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2022-07-13	2027-07-13	No	4	X	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	426,931	Direct

Footnotes

The Reporting Persons exercised these warrants on a "cashless" basis, pursuant to the terms of the warrant to purchase stock, resulting in Provention Bio, Inc. withholding 2,190,549 shares of Common Stock and issuing the remaining 6,688,474 shares of Common Stock to Sessa Capital (Master), L.P. The disposition of the warrants and the resulting issuance of the net shares of Common Stock were exempt under Rule 16b-6(b) under the Securities Exchange Act of 1934, as amended.
These securities of Provention Bio, Inc. are beneficially owned by (i) Sessa Capital (Master), L.P. (the "Fund"), as a result of direct beneficial ownership of the securities, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P. indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.
Calculated based on the closing price or last reported sale price of a share of Common Stock for the business day immediately prior to the date of the warrant exercise.
Held directly by Mr. Petry.